Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab with or without Ipilimumab in Refractory Metastatic Squamous Cell Carcinoma of the Anal Canal
NCT02314169Phase 2Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- May 2015
- Primary completion
- Feb 2025
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 2, randomised, open-label trial of nivolumab in anal canal squamous cell carcinoma (SCCA) (3 arms), sponsored by National Cancer Institute. Primary endpoints: Overall Response Rate up to 2 years and Progression-Free Survival up to 2 years. Started May 2015; status: active, not recruiting.
02
Drugs
03
Conditions
anal canal squamous cell carcinoma (SCCA)
Beyond the preview
Go deeper on NCT02314169.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02314169.